Recent advances in ECMO for severe ARDS

Recent advances in ECMO for severe ARDS

Anesthesiology · Critical Care

Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure characterized by acute inflammatory lung injury, impaired gas exchange, and severe hypoxemia. Despite advances in lung-protective ventilation and prone positioning, some patients develop refractory respiratory failure requiring extracorporeal membrane oxygenation (ECMO). Venovenous ECMO (VV-ECMO) provides temporary respiratory support by facilitating oxygenation and carbon dioxide removal while allowing reduced ventilator intensity. Recent developments in patient selection, cannulation strategies, anticoagulation, and awake ECMO have expanded its clinical applications.[1][2]Advances in patient selection and ECMO initiationThe 2024 American Thoracic Society (ATS) clinical practice guideline conditionally recommends VV-ECMO in selected patients with severe ARDS, although the certainty of evidence remains low[1]Patients with potentially reversible respiratory failure that remains refractory to optimized conventional management should be evaluated for ECMO supportThe Extracorporeal Life Support Organization (ELSO) recommends considering ECMO in patients with severe refractory hypoxemia, including a PaO₂/FiO₂ ratio below 80 mmHg, or severe hypercapnic respiratory failure despite optimal management[2]Early referral to experienced ECMO centers is important because prolonged invasive mechanical ventilation before ECMO initiation is associated with poorer outcomes[2]Lung-protective ventilation during ECMOVV-ECMO facilitates ultraprotective ventilation by reducing the need for injurious ventilator settings and limiting further ventilator-induced lung injury[2]Ventilator management during ECMO focuses on minimizing tidal volume, respiratory rate, and airway pressures while maintaining adequate gas exchangeIndividualized positive end-expiratory pressure (PEEP) adjustment remains important to support alveolar recruitment and prevent further lung injury[1][2]The 2024 ATS guideline also supports established ARDS interventions, including prone positioning for more than 12 hours daily in patients with severe ARDS[1]Emerging approaches to ECMO deliveryAwake VV-ECMO is an evolving approach in which selected patients receive extracorporeal respiratory support without conventional invasive mechanical ventilation or undergo extubation while receiving ECMOAvoiding prolonged sedation and invasive ventilation may facilitate spontaneous breathing, communication, and early physical rehabilitation[3]However, awake ECMO requires careful patient selection because spontaneous breathing may increase respiratory effort and self-inflicted lung injury, while cannula displacement remains an important procedural concern[3]Dual-lumen cannulation and alternative venous cannulation configurations provide options for individualized circuit management according to patient anatomy and clinical requirements[2]Anticoagulation and circuit-related advancesBleeding and thrombosis remain major complications of ECMO because of interactions between the extracorporeal circuit, underlying critical illness, and systemic anticoagulation[4]Unfractionated heparin remains a commonly used anticoagulant, while Bivalirudin is an alternative in selected clinical circumstancesEmerging monitoring approaches include anti-Xa assessment, platelet function testing, and viscoelastic testing to support individualized anticoagulation management[4]Improvements in circuit biocompatibility and hemostatic monitoring are important areas of ongoing development[4]Clinical applications of extracorporeal supportSupport modalityPrincipal clinical roleVV-ECMORespiratory support through oxygenation and carbon dioxide removal.Venoarterial ECMOCombined circulatory and respiratory support when cardiac dysfunction accompanies respiratory failure.Extracorporeal carbon dioxide removal (ECCO₂R)Primarily supports carbon dioxide clearance with comparatively limited oxygenation capacity.These modalities have different physiological objectives, and VV-ECMO remains the principal configuration for isolated severe respiratory failure. Evidence is currently insufficient to support routine ECCO₂R use in ARDS.[2][5]ConclusionRecent advances in ECMO have expanded its role in managing selected patients with severe ARDS through improved patient selection, ultraprotective ventilation, awake support strategies, and individualized anticoagulation. VV-ECMO remains an invasive and resource-intensive intervention that requires experienced multidisciplinary teams. Appropriate timing, careful monitoring, and integration with conventional ARDS management are essential to optimizing clinical outcomes.Reference(s):1. Qadir N, Sahetya S, Munshi L, et al. An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;209(1):24-36. doi:10.1164/rccm.202311-2011ST. https://pmc.ncbi.nlm.nih.gov/articles/PMC10870893/2. Tonna JE, Abrams D, Brodie D, et al. Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021;67(6):601-610. doi:10.1097/MAT.0000000000001432. https://pmc.ncbi.nlm.nih.gov/articles/PMC8315725/3. Chau VQ, Kalapurakal G, Imamura T, et al. A Contemporary Guide of Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock. J Cardiovasc Dev Dis. 2025;12(12):475. Published 2025 Dec 2. doi:10.3390/jcdd12120475. https://pmc.ncbi.nlm.nih.gov/articles/PMC12734369/4. Jung C, Stueber T, Mirus M, Heubner L, Spieth PM. Anticoagulation in venovenous extracorporeal membrane oxygenation. Front Med (Lausanne). 2025;12:1530411. Published 2025 Mar 4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11913846/ doi:10.3389/fmed.2025.1530411. 5. Xie K, Jing H, Guan S, et al. Extracorporeal membrane oxygenation technology for adults: an evidence mapping based on systematic reviews. Eur J Med Res. 2024;29(1):247. Published 2024 Apr 22. doi:10.1186/s40001-024-01837-0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11036703/